Literature DB >> 29590458

Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed.

Laure Gallay1,2, Julie Bourgeois-Vionnet3, Bastien Joubert3, Nathalie Streichenberger2,4, Arnaud Hot1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29590458      PMCID： PMC5960993          DOI： 10.1093/neuonc/noy031

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  6 in total

Review 1.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

3.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

4.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

Review 5.  Immune checkpoint inhibitor-related myocarditis.

Authors:  Kazuko Tajiri; Kazutaka Aonuma; Ikuo Sekine
Journal:  Jpn J Clin Oncol       Date:  2018-01-01       Impact factor: 3.019

Review 6.  Neurological toxicities associated with immune-checkpoint inhibitors.

Authors:  Mehdi Touat; Daniel Talmasov; Damien Ricard; Dimitri Psimaras
Journal:  Curr Opin Neurol       Date:  2017-12       Impact factor: 5.710
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.